.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Cantor Fitzgerald
Chubb
Federal Trade Commission
Julphar
McKesson
AstraZeneca
Deloitte
Daiichi Sankyo

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,341,744

« Back to Dashboard

Which drugs does patent 7,341,744 protect, and when does it expire?


Patent 7,341,744 protects FULYZAQ and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 7,341,744

Title:Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
Inventor(s): Rozhon; Edward James (El Granada, CA), Khandwala; Atul S. (San Carlos, CA), Sabouni; Akram (Fairport, NY), Balwani; Gul P. (Fremont, CA), Chan; Jody Wai-Han (Mountain View, CA), Sesin; David F. (San Carlos, CA)
Assignee: Napo Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:09/712,033
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► Subscribe SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,341,744

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,323,195Enteric formulations of proanthocyanidin polymer antidiarrheal compositions► Subscribe
8,574,634Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,341,744

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria430477► Subscribe
Australia2030302► Subscribe
Australia4988197► Subscribe
Australia775330► Subscribe
Canada2269078► Subscribe
Germany69739394► Subscribe
Denmark0935417► Subscribe
European Patent Office0935417► Subscribe
European Patent Office2060183► Subscribe
European Patent Office2255661► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Dow
McKinsey
Deloitte
Fuji
Healthtrust
Mallinckrodt
Novartis
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot